CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Keck Hospital of University of Southern California (USC) in Los Angeles, CA has been added as a clinical site in the company’s ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The Keck Hospital of USC is a 401-bed acute care hospital for the Keck Medical Center of USC, a system that comprises more than 500 faculty physicians. Patrick Hsieh, MD, Director of Neurosurgery Spine Program and Associate Professor of Neurological Surgery, has been named Principal Investigator at the site.
Help employers find you! Check out all the jobs and post your resume.
